Johnson & Johnson has received an offer for its sterilization unit. The New Brunswick, NJ-based company said Fortive is seeking to acquire the business for $2.7 billion.

The sterilization business is part of the Ethicon division and earned about $775 million in sales in 2017. J&J has 120 days to accept the offer and if the deal goes through it could close no later than early 2019.

Fortive said it would finance the acquisition through debt or equity and with available cash. The company said it expects the deal to add to adjusted earnings in the first full year after the transaction.

“As we balance the interests of all our stakeholders to deliver the greatest value to customers, healthcare providers and shareholders, we must continuously assess strategic fit and explore alternatives for our businesses,” Shlomi Nachman, Company Group Chairman, Interventional Solutions and Specialty Surgery with Johnson & Johnson, said in a release. “ASP has a long history of pioneering infection prevention technology, and we are confident that Fortive would be well-positioned to continue to drive the business toward achieving its full potential.”

This is the latest in what is becoming a long line of divestitures for J&J. It’s also part of a series of significant changes within the firm’s medtech offerings. Back in 2016, J&J’s medtech division was in a state of turmoil. The company cut about 6% of its workforce in the device space to reduce costs.

In recent years, the device side has performed a bit better– but divestitures have continued. Early last year, J&J turned heads when it announced it was selling its Codman Neurosurgery Business to Integra Lifesciences for $1.05 billion.

But even before the deal closed, Codman made an acquisition of its own – picking up Neuravi Limited, a private stroke care company, for an undisclosed sum.

J&J is also planning to sell its diabetes unit, which for the past few years has had sluggish performance. In March, the company received a $2.1 billion offer from Platinum Equity to acquire its diabetes unit, LifeScan.

Prior to the offer, J&J had announced plans to shut down Animas Corp., which once provided insulin pumps to 90,000 patients. J&J said those insulin pump users would have the option to transfer over to Medtronic pumps.

Source: https://www.mddionline.com/no-end-sight-jj-divestitures?ADTRK=UBM&elq_mid=4498&elq_cid=8092855

About iData Research

iData Research (www.idataresearch.com) is an international market research and consulting firm, dedicated to providing the best in business intelligence for the medical device industry. Our research empowers our clients by providing them with the necessary tools to achieve their goals and do it right the first time. iData covers research in: Spinal Implants and VCF, Spinal MIS, Orthopedic Soft Tissue Repair and Regeneration, Orthopedic Trauma, Large & Small Joints, Laparoscopy, Urology, Gynecology, Endoscopy, Dental Operatory Equipment, Dental Material, Dental Lasers, Dental Prosthetics, Dental CAD/CAM, Dental Bone Graft Substitutes, Ultrasound, X-Ray Imaging, Diagnostic Imaging, Oncology, Ophthalmics, Vascular Access, Interventional Cardiology, Cardiac Surgery, Cardiac Rhythm Management, Electrophysiology, Operating Room Equipment, Surgical Microscopes, Robotics and Surgical Navigation, Anesthesiology, Wound Management and more.

We have built a reputation and earned our clients’ trust based on consistent and uniquely intelligent research that allows our customers to make confident decisions and impact their businesses. A combination of market expertise and over a decade of experience has resulted in a deep understanding of the medical device industry that has inspired innovation and propelled our clients to success.